Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis
It is an open label, phase II study involved receiving albumin-bound paclitaxel plus S-1 combined with sintilimab and bevacizumab in patients with gastric cancer peritoneal metastasis.
Gastric Cancer Peritoneal Metastases
DRUG: albumin-bound paclitaxel (260 mg/m2, d1)|DRUG: S-1|DRUG: sintilimab|DRUG: bevacizumab
Overall survival rate, 1 year
Progression free survival, 1 year|Ascites drainage-free survival, 1 year|Objective Response Rate, 1 year
It is an open label, phase II study involved receiving albumin-bound paclitaxel plus S-1 combined with sintilimab and bevacizumab in patients with gastric cancer peritoneal metastasis.